Shilpa Medicare's Subsidiary Enters Strategic Partnership with Orion Corporation for Recombinant Human Albumin in Europe

Shilpa Biocare, a wholly owned subsidiary of Shilpa Medicare, has entered into a strategic partnership with Orion Corporation, a globally recognized pharmaceutical company based in Finland. The partnership aims to commercialize Shilpa's Recombinant Human Albumin in Europe. This agreement provides Orion with the exclusive right to distribute, market, and sell Shilpa’s Recombinant Human Albumin in Europe. Shilpa Medicare's recombinant human albumin is developed using a robust non-human expression system, ensuring high safety, scalability, and virus-free production. This partnership is a significant step in Shilpa’s expansion into global biosimilar and biopharmaceutical markets, leveraging Orion’s strong regional presence, regulatory expertise, and well-established commercial infrastructure.